| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-211 | |
| Phytochemical name or plant extracts | Mulberry root bark extracts | |
| PMID | 26926171 | |
| Literature evidence | BACKGROUND: Mulberry root bark was shown to induce cyclin D1 proteasomal degradation in the human colorectal cancer cells. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Extract | |
| Source of phytochemicals or plant Extracts | Morus alba | |
| Geographical availability | China North-Central, China South-Central | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | Cyclin D1 | |
| Gene or Protein evidence | MRB effectively decreased cyclin D1 protein level in human colorectal cancer cells and breast cancer cells, but not in hepatocellular carcinoma cells. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | Inhibition of proteasomal degradation by MG132 attenuated MRB-mediated cyclin D1 downregulation and the half-life of cyclin D1 was decreased in the cells treated with MRB. In addition, MRB increased phosphorylation of cyclin D1 at threonine-286 and a point mutation of threonine-286 to alanine attenuated MRB-mediated cyclin D1 degradation. | |
| Cell line/ mice model | MDA-MB-231, MCF-7, HCT116, SW480, LoVo | |
| Additional information | MRB has anti-cancer activity by inducing cyclin D1 proteasomal degradation through cyclin D1 nuclear export via GSK3β-dependent threonine-286 phosphorylation. These findings suggest that possibly its extract could be used for treating colorectal cancer. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:30051955-2 | |
| Safety | NA |